カテゴリー： Market Monitor Global, 世界, 医療/バイオ

弱毒生インフルエンザワクチン（LAIV）の世界市場見通し2023年-2029年

◆英語タイトル：Live Attenuated Influenza Vaccine (LAIV) Market, Global Outlook and Forecast 2023-2029
	◆商品コード：MMG23LY8508 ◆発行会社（リサーチ会社）：Market Monitor Global ◆発行日：2023年7月（※2025年版があります。お問い合わせください。） ◆ページ数：74 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品＆ヘルスケア

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥468,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥608,400	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥702,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Live Attenuated Influenza Vaccine (LAIV) Market 調査レポートは次の情報を含め、グローバルにおけるの弱毒生インフルエンザワクチン（LAIV）市場規模と予測を収録しています。・世界の弱毒生インフルエンザワクチン（LAIV）市場：売上、2018年-2023年、2024年-2029年
・世界の弱毒生インフルエンザワクチン（LAIV）市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の弱毒生インフルエンザワクチン（LAIV）市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「3価インフルエンザワクチン」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

弱毒生インフルエンザワクチン（LAIV）のグローバル主要企業は、Sanofi Pasteur、 AstraZeneca、 CSL、 Abbott、 GlaxoSmithKline、 Serum Institute、 Fluenz Tetra、 Cytiva、 BioDiem、 FluMist、 GSK、 ChangChun High & New Technology、 BCHT Biotechnologyなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、弱毒生インフルエンザワクチン（LAIV）のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の弱毒生インフルエンザワクチン（LAIV）市場：タイプ別、2018年-2023年、2024年-2029年
世界の弱毒生インフルエンザワクチン（LAIV）市場：タイプ別市場シェア、2022年
・3価インフルエンザワクチン、4価インフルエンザワクチン

世界の弱毒生インフルエンザワクチン（LAIV）市場：用途別、2018年-2023年、2024年-2029年
世界の弱毒生インフルエンザワクチン（LAIV）市場：用途別市場シェア、2022年
・病院、診療所、衛生行政機関、その他

世界の弱毒生インフルエンザワクチン（LAIV）市場：地域・国別、2018年-2023年、2024年-2029年
世界の弱毒生インフルエンザワクチン（LAIV）市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における弱毒生インフルエンザワクチン（LAIV）のグローバル売上、2018年-2023年
・主要企業における弱毒生インフルエンザワクチン（LAIV）のグローバル売上シェア、2022年
・主要企業における弱毒生インフルエンザワクチン（LAIV）のグローバル販売量、2018年-2023年
・主要企業における弱毒生インフルエンザワクチン（LAIV）のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Sanofi Pasteur、 AstraZeneca、 CSL、 Abbott、 GlaxoSmithKline、 Serum Institute、 Fluenz Tetra、 Cytiva、 BioDiem、 FluMist、 GSK、 ChangChun High & New Technology、 BCHT Biotechnology

*************************************************************

・調査・分析レポートの概要
弱毒生インフルエンザワクチン（LAIV）市場の定義
市場セグメント
世界の弱毒生インフルエンザワクチン（LAIV）市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の弱毒生インフルエンザワクチン（LAIV）市場規模
世界の弱毒生インフルエンザワクチン（LAIV）市場規模：2022年 VS 2029年
世界の弱毒生インフルエンザワクチン（LAIV）市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの弱毒生インフルエンザワクチン（LAIV）の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の弱毒生インフルエンザワクチン（LAIV）製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：3価インフルエンザワクチン、4価インフルエンザワクチン
弱毒生インフルエンザワクチン（LAIV）のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、診療所、衛生行政機関、その他
弱毒生インフルエンザワクチン（LAIV）の用途別グローバル売上・予測

・地域別市場分析
地域別弱毒生インフルエンザワクチン（LAIV）市場規模 2022年と2029年
地域別弱毒生インフルエンザワクチン（LAIV）売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Sanofi Pasteur、 AstraZeneca、 CSL、 Abbott、 GlaxoSmithKline、 Serum Institute、 Fluenz Tetra、 Cytiva、 BioDiem、 FluMist、 GSK、 ChangChun High & New Technology、 BCHT Biotechnology
...

This report aims to provide a comprehensive presentation of the global market for Live Attenuated Influenza Vaccine (LAIV), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Live Attenuated Influenza Vaccine (LAIV). This report contains market size and forecasts of Live Attenuated Influenza Vaccine (LAIV) in global, including the following market information:
Global Live Attenuated Influenza Vaccine (LAIV) Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Live Attenuated Influenza Vaccine (LAIV) Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Live Attenuated Influenza Vaccine (LAIV) companies in 2022 (%)
The global Live Attenuated Influenza Vaccine (LAIV) market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Trivalent Flu Vaccine Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Live Attenuated Influenza Vaccine (LAIV) include Sanofi Pasteur, AstraZeneca, CSL, Abbott, GlaxoSmithKline, Serum Institute, Fluenz Tetra, Cytiva and BioDiem, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Live Attenuated Influenza Vaccine (LAIV) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Live Attenuated Influenza Vaccine (LAIV) Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Live Attenuated Influenza Vaccine (LAIV) Market Segment Percentages, by Type, 2022 (%)
Trivalent Flu Vaccine
Quadrivalent Flu Vaccine
Global Live Attenuated Influenza Vaccine (LAIV) Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Live Attenuated Influenza Vaccine (LAIV) Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Public Health Agency
Other
Global Live Attenuated Influenza Vaccine (LAIV) Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Live Attenuated Influenza Vaccine (LAIV) Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Live Attenuated Influenza Vaccine (LAIV) revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Live Attenuated Influenza Vaccine (LAIV) revenues share in global market, 2022 (%)
Key companies Live Attenuated Influenza Vaccine (LAIV) sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Live Attenuated Influenza Vaccine (LAIV) sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi Pasteur
AstraZeneca
CSL
Abbott
GlaxoSmithKline
Serum Institute
Fluenz Tetra
Cytiva
BioDiem
FluMist
GSK
ChangChun High & New Technology
BCHT Biotechnology
Outline of Major Chapters:
Chapter 1: Introduces the definition of Live Attenuated Influenza Vaccine (LAIV), market overview.
Chapter 2: Global Live Attenuated Influenza Vaccine (LAIV) market size in revenue and volume.
Chapter 3: Detailed analysis of Live Attenuated Influenza Vaccine (LAIV) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Live Attenuated Influenza Vaccine (LAIV) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Live Attenuated Influenza Vaccine (LAIV) capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Live Attenuated Influenza Vaccine (LAIV) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Live Attenuated Influenza Vaccine (LAIV) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Live Attenuated Influenza Vaccine (LAIV) Overall Market Size
2.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size: 2022 VS 2029
2.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Live Attenuated Influenza Vaccine (LAIV) Sales: 2018-2029
3 Company Landscape
3.1 Top Live Attenuated Influenza Vaccine (LAIV) Players in Global Market
3.2 Top Global Live Attenuated Influenza Vaccine (LAIV) Companies Ranked by Revenue
3.3 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Companies
3.4 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Companies
3.5 Global Live Attenuated Influenza Vaccine (LAIV) Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Live Attenuated Influenza Vaccine (LAIV) Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Live Attenuated Influenza Vaccine (LAIV) Product Type
3.8 Tier 1, Tier 2 and Tier 3 Live Attenuated Influenza Vaccine (LAIV) Players in Global Market
3.8.1 List of Global Tier 1 Live Attenuated Influenza Vaccine (LAIV) Companies
3.8.2 List of Global Tier 2 and Tier 3 Live Attenuated Influenza Vaccine (LAIV) Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Live Attenuated Influenza Vaccine (LAIV) Market Size Markets, 2022 & 2029
4.1.2 Trivalent Flu Vaccine
4.1.3 Quadrivalent Flu Vaccine
4.2 By Type – Global Live Attenuated Influenza Vaccine (LAIV) Revenue & Forecasts
4.2.1 By Type – Global Live Attenuated Influenza Vaccine (LAIV) Revenue, 2018-2023
4.2.2 By Type – Global Live Attenuated Influenza Vaccine (LAIV) Revenue, 2024-2029
4.2.3 By Type – Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share, 2018-2029
4.3 By Type – Global Live Attenuated Influenza Vaccine (LAIV) Sales & Forecasts
4.3.1 By Type – Global Live Attenuated Influenza Vaccine (LAIV) Sales, 2018-2023
4.3.2 By Type – Global Live Attenuated Influenza Vaccine (LAIV) Sales, 2024-2029
4.3.3 By Type – Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share, 2018-2029
4.4 By Type – Global Live Attenuated Influenza Vaccine (LAIV) Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Live Attenuated Influenza Vaccine (LAIV) Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Public Health Agency
5.1.5 Other
5.2 By Application – Global Live Attenuated Influenza Vaccine (LAIV) Revenue & Forecasts
5.2.1 By Application – Global Live Attenuated Influenza Vaccine (LAIV) Revenue, 2018-2023
5.2.2 By Application – Global Live Attenuated Influenza Vaccine (LAIV) Revenue, 2024-2029
5.2.3 By Application – Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share, 2018-2029
5.3 By Application – Global Live Attenuated Influenza Vaccine (LAIV) Sales & Forecasts
5.3.1 By Application – Global Live Attenuated Influenza Vaccine (LAIV) Sales, 2018-2023
5.3.2 By Application – Global Live Attenuated Influenza Vaccine (LAIV) Sales, 2024-2029
5.3.3 By Application – Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share, 2018-2029
5.4 By Application – Global Live Attenuated Influenza Vaccine (LAIV) Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Live Attenuated Influenza Vaccine (LAIV) Market Size, 2022 & 2029
6.2 By Region – Global Live Attenuated Influenza Vaccine (LAIV) Revenue & Forecasts
6.2.1 By Region – Global Live Attenuated Influenza Vaccine (LAIV) Revenue, 2018-2023
6.2.2 By Region – Global Live Attenuated Influenza Vaccine (LAIV) Revenue, 2024-2029
6.2.3 By Region – Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share, 2018-2029
6.3 By Region – Global Live Attenuated Influenza Vaccine (LAIV) Sales & Forecasts
6.3.1 By Region – Global Live Attenuated Influenza Vaccine (LAIV) Sales, 2018-2023
6.3.2 By Region – Global Live Attenuated Influenza Vaccine (LAIV) Sales, 2024-2029
6.3.3 By Region – Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Live Attenuated Influenza Vaccine (LAIV) Revenue, 2018-2029
6.4.2 By Country – North America Live Attenuated Influenza Vaccine (LAIV) Sales, 2018-2029
6.4.3 US Live Attenuated Influenza Vaccine (LAIV) Market Size, 2018-2029
6.4.4 Canada Live Attenuated Influenza Vaccine (LAIV) Market Size, 2018-2029
6.4.5 Mexico Live Attenuated Influenza Vaccine (LAIV) Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Live Attenuated Influenza Vaccine (LAIV) Revenue, 2018-2029
6.5.2 By Country – Europe Live Attenuated Influenza Vaccine (LAIV) Sales, 2018-2029
6.5.3 Germany Live Attenuated Influenza Vaccine (LAIV) Market Size, 2018-2029
6.5.4 France Live Attenuated Influenza Vaccine (LAIV) Market Size, 2018-2029
6.5.5 U.K. Live Attenuated Influenza Vaccine (LAIV) Market Size, 2018-2029
6.5.6 Italy Live Attenuated Influenza Vaccine (LAIV) Market Size, 2018-2029
6.5.7 Russia Live Attenuated Influenza Vaccine (LAIV) Market Size, 2018-2029
6.5.8 Nordic Countries Live Attenuated Influenza Vaccine (LAIV) Market Size, 2018-2029
6.5.9 Benelux Live Attenuated Influenza Vaccine (LAIV) Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Live Attenuated Influenza Vaccine (LAIV) Revenue, 2018-2029
6.6.2 By Region – Asia Live Attenuated Influenza Vaccine (LAIV) Sales, 2018-2029
6.6.3 China Live Attenuated Influenza Vaccine (LAIV) Market Size, 2018-2029
6.6.4 Japan Live Attenuated Influenza Vaccine (LAIV) Market Size, 2018-2029
6.6.5 South Korea Live Attenuated Influenza Vaccine (LAIV) Market Size, 2018-2029
6.6.6 Southeast Asia Live Attenuated Influenza Vaccine (LAIV) Market Size, 2018-2029
6.6.7 India Live Attenuated Influenza Vaccine (LAIV) Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Live Attenuated Influenza Vaccine (LAIV) Revenue, 2018-2029
6.7.2 By Country – South America Live Attenuated Influenza Vaccine (LAIV) Sales, 2018-2029
6.7.3 Brazil Live Attenuated Influenza Vaccine (LAIV) Market Size, 2018-2029
6.7.4 Argentina Live Attenuated Influenza Vaccine (LAIV) Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales, 2018-2029
6.8.3 Turkey Live Attenuated Influenza Vaccine (LAIV) Market Size, 2018-2029
6.8.4 Israel Live Attenuated Influenza Vaccine (LAIV) Market Size, 2018-2029
6.8.5 Saudi Arabia Live Attenuated Influenza Vaccine (LAIV) Market Size, 2018-2029
6.8.6 UAE Live Attenuated Influenza Vaccine (LAIV) Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Sanofi Pasteur
7.1.1 Sanofi Pasteur Company Summary
7.1.2 Sanofi Pasteur Business Overview
7.1.3 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Major Product Offerings
7.1.4 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales and Revenue in Global (2018-2023)
7.1.5 Sanofi Pasteur Key News & Latest Developments
7.2 AstraZeneca
7.2.1 AstraZeneca Company Summary
7.2.2 AstraZeneca Business Overview
7.2.3 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Major Product Offerings
7.2.4 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales and Revenue in Global (2018-2023)
7.2.5 AstraZeneca Key News & Latest Developments
7.3 CSL
7.3.1 CSL Company Summary
7.3.2 CSL Business Overview
7.3.3 CSL Live Attenuated Influenza Vaccine (LAIV) Major Product Offerings
7.3.4 CSL Live Attenuated Influenza Vaccine (LAIV) Sales and Revenue in Global (2018-2023)
7.3.5 CSL Key News & Latest Developments
7.4 Abbott
7.4.1 Abbott Company Summary
7.4.2 Abbott Business Overview
7.4.3 Abbott Live Attenuated Influenza Vaccine (LAIV) Major Product Offerings
7.4.4 Abbott Live Attenuated Influenza Vaccine (LAIV) Sales and Revenue in Global (2018-2023)
7.4.5 Abbott Key News & Latest Developments
7.5 GlaxoSmithKline
7.5.1 GlaxoSmithKline Company Summary
7.5.2 GlaxoSmithKline Business Overview
7.5.3 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Major Product Offerings
7.5.4 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales and Revenue in Global (2018-2023)
7.5.5 GlaxoSmithKline Key News & Latest Developments
7.6 Serum Institute
7.6.1 Serum Institute Company Summary
7.6.2 Serum Institute Business Overview
7.6.3 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Major Product Offerings
7.6.4 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales and Revenue in Global (2018-2023)
7.6.5 Serum Institute Key News & Latest Developments
7.7 Fluenz Tetra
7.7.1 Fluenz Tetra Company Summary
7.7.2 Fluenz Tetra Business Overview
7.7.3 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Major Product Offerings
7.7.4 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales and Revenue in Global (2018-2023)
7.7.5 Fluenz Tetra Key News & Latest Developments
7.8 Cytiva
7.8.1 Cytiva Company Summary
7.8.2 Cytiva Business Overview
7.8.3 Cytiva Live Attenuated Influenza Vaccine (LAIV) Major Product Offerings
7.8.4 Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales and Revenue in Global (2018-2023)
7.8.5 Cytiva Key News & Latest Developments
7.9 BioDiem
7.9.1 BioDiem Company Summary
7.9.2 BioDiem Business Overview
7.9.3 BioDiem Live Attenuated Influenza Vaccine (LAIV) Major Product Offerings
7.9.4 BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales and Revenue in Global (2018-2023)
7.9.5 BioDiem Key News & Latest Developments
7.10 FluMist
7.10.1 FluMist Company Summary
7.10.2 FluMist Business Overview
7.10.3 FluMist Live Attenuated Influenza Vaccine (LAIV) Major Product Offerings
7.10.4 FluMist Live Attenuated Influenza Vaccine (LAIV) Sales and Revenue in Global (2018-2023)
7.10.5 FluMist Key News & Latest Developments
7.11 GSK
7.11.1 GSK Company Summary
7.11.2 GSK Live Attenuated Influenza Vaccine (LAIV) Business Overview
7.11.3 GSK Live Attenuated Influenza Vaccine (LAIV) Major Product Offerings
7.11.4 GSK Live Attenuated Influenza Vaccine (LAIV) Sales and Revenue in Global (2018-2023)
7.11.5 GSK Key News & Latest Developments
7.12 ChangChun High & New Technology
7.12.1 ChangChun High & New Technology Company Summary
7.12.2 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Business Overview
7.12.3 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Major Product Offerings
7.12.4 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Sales and Revenue in Global (2018-2023)
7.12.5 ChangChun High & New Technology Key News & Latest Developments
7.13 BCHT Biotechnology
7.13.1 BCHT Biotechnology Company Summary
7.13.2 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Business Overview
7.13.3 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Major Product Offerings
7.13.4 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales and Revenue in Global (2018-2023)
7.13.5 BCHT Biotechnology Key News & Latest Developments
8 Global Live Attenuated Influenza Vaccine (LAIV) Production Capacity, Analysis
8.1 Global Live Attenuated Influenza Vaccine (LAIV) Production Capacity, 2018-2029
8.2 Live Attenuated Influenza Vaccine (LAIV) Production Capacity of Key Manufacturers in Global Market
8.3 Global Live Attenuated Influenza Vaccine (LAIV) Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Live Attenuated Influenza Vaccine (LAIV) Supply Chain Analysis
10.1 Live Attenuated Influenza Vaccine (LAIV) Industry Value Chain
10.2 Live Attenuated Influenza Vaccine (LAIV) Upstream Market
10.3 Live Attenuated Influenza Vaccine (LAIV) Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Live Attenuated Influenza Vaccine (LAIV) Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Live Attenuated Influenza Vaccine (LAIV) in Global Market
Table 2. Top Live Attenuated Influenza Vaccine (LAIV) Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Companies, 2018-2023
Table 5. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Companies, (K Units), 2018-2023
Table 6. Global Live Attenuated Influenza Vaccine (LAIV) Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Live Attenuated Influenza Vaccine (LAIV) Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Live Attenuated Influenza Vaccine (LAIV) Product Type
Table 9. List of Global Tier 1 Live Attenuated Influenza Vaccine (LAIV) Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Live Attenuated Influenza Vaccine (LAIV) Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Live Attenuated Influenza Vaccine (LAIV) Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Live Attenuated Influenza Vaccine (LAIV) Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), 2018-2023
Table 15. By Type - Global Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), 2024-2029
Table 16. By Application – Global Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Live Attenuated Influenza Vaccine (LAIV) Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Live Attenuated Influenza Vaccine (LAIV) Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), 2018-2023
Table 20. By Application - Global Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), 2024-2029
Table 21. By Region – Global Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Live Attenuated Influenza Vaccine (LAIV) Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Live Attenuated Influenza Vaccine (LAIV) Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), 2018-2023
Table 25. By Region - Global Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), 2024-2029
Table 26. By Country - North America Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Live Attenuated Influenza Vaccine (LAIV) Sales, (K Units), 2018-2023
Table 29. By Country - North America Live Attenuated Influenza Vaccine (LAIV) Sales, (K Units), 2024-2029
Table 30. By Country - Europe Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Live Attenuated Influenza Vaccine (LAIV) Sales, (K Units), 2018-2023
Table 33. By Country - Europe Live Attenuated Influenza Vaccine (LAIV) Sales, (K Units), 2024-2029
Table 34. By Region - Asia Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Live Attenuated Influenza Vaccine (LAIV) Sales, (K Units), 2018-2023
Table 37. By Region - Asia Live Attenuated Influenza Vaccine (LAIV) Sales, (K Units), 2024-2029
Table 38. By Country - South America Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Live Attenuated Influenza Vaccine (LAIV) Sales, (K Units), 2018-2023
Table 41. By Country - South America Live Attenuated Influenza Vaccine (LAIV) Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales, (K Units), 2024-2029
Table 46. Sanofi Pasteur Company Summary
Table 47. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Offerings
Table 48. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. Sanofi Pasteur Key News & Latest Developments
Table 50. AstraZeneca Company Summary
Table 51. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Offerings
Table 52. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. AstraZeneca Key News & Latest Developments
Table 54. CSL Company Summary
Table 55. CSL Live Attenuated Influenza Vaccine (LAIV) Product Offerings
Table 56. CSL Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. CSL Key News & Latest Developments
Table 58. Abbott Company Summary
Table 59. Abbott Live Attenuated Influenza Vaccine (LAIV) Product Offerings
Table 60. Abbott Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. Abbott Key News & Latest Developments
Table 62. GlaxoSmithKline Company Summary
Table 63. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Offerings
Table 64. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. GlaxoSmithKline Key News & Latest Developments
Table 66. Serum Institute Company Summary
Table 67. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Offerings
Table 68. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. Serum Institute Key News & Latest Developments
Table 70. Fluenz Tetra Company Summary
Table 71. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Offerings
Table 72. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. Fluenz Tetra Key News & Latest Developments
Table 74. Cytiva Company Summary
Table 75. Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Offerings
Table 76. Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. Cytiva Key News & Latest Developments
Table 78. BioDiem Company Summary
Table 79. BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Offerings
Table 80. BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. BioDiem Key News & Latest Developments
Table 82. FluMist Company Summary
Table 83. FluMist Live Attenuated Influenza Vaccine (LAIV) Product Offerings
Table 84. FluMist Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 85. FluMist Key News & Latest Developments
Table 86. GSK Company Summary
Table 87. GSK Live Attenuated Influenza Vaccine (LAIV) Product Offerings
Table 88. GSK Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 89. GSK Key News & Latest Developments
Table 90. ChangChun High & New Technology Company Summary
Table 91. ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Product Offerings
Table 92. ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 93. ChangChun High & New Technology Key News & Latest Developments
Table 94. BCHT Biotechnology Company Summary
Table 95. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Offerings
Table 96. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 97. BCHT Biotechnology Key News & Latest Developments
Table 98. Live Attenuated Influenza Vaccine (LAIV) Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 99. Global Live Attenuated Influenza Vaccine (LAIV) Capacity Market Share of Key Manufacturers, 2021-2023
Table 100. Global Live Attenuated Influenza Vaccine (LAIV) Production by Region, 2018-2023 (K Units)
Table 101. Global Live Attenuated Influenza Vaccine (LAIV) Production by Region, 2024-2029 (K Units)
Table 102. Live Attenuated Influenza Vaccine (LAIV) Market Opportunities & Trends in Global Market
Table 103. Live Attenuated Influenza Vaccine (LAIV) Market Drivers in Global Market
Table 104. Live Attenuated Influenza Vaccine (LAIV) Market Restraints in Global Market
Table 105. Live Attenuated Influenza Vaccine (LAIV) Raw Materials
Table 106. Live Attenuated Influenza Vaccine (LAIV) Raw Materials Suppliers in Global Market
Table 107. Typical Live Attenuated Influenza Vaccine (LAIV) Downstream
Table 108. Live Attenuated Influenza Vaccine (LAIV) Downstream Clients in Global Market
Table 109. Live Attenuated Influenza Vaccine (LAIV) Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Live Attenuated Influenza Vaccine (LAIV) Segment by Type in 2022
Figure 2. Live Attenuated Influenza Vaccine (LAIV) Segment by Application in 2022
Figure 3. Global Live Attenuated Influenza Vaccine (LAIV) Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Live Attenuated Influenza Vaccine (LAIV) Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Live Attenuated Influenza Vaccine (LAIV) Revenue, 2018-2029 (US$, Mn)
Figure 7. Live Attenuated Influenza Vaccine (LAIV) Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Live Attenuated Influenza Vaccine (LAIV) Revenue in 2022
Figure 9. By Type - Global Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share, 2018-2029
Figure 11. By Type - Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share, 2018-2029
Figure 12. By Type - Global Live Attenuated Influenza Vaccine (LAIV) Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share, 2018-2029
Figure 15. By Application - Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share, 2018-2029
Figure 16. By Application - Global Live Attenuated Influenza Vaccine (LAIV) Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share, 2018-2029
Figure 20. By Region - Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share, 2018-2029
Figure 21. By Country - North America Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share, 2018-2029
Figure 22. By Country - North America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share, 2018-2029
Figure 23. US Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Live Attenuated Influenza Vaccine (LAIV) Sales Market Share, 2018-2029
Figure 28. Germany Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2029
Figure 29. France Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Live Attenuated Influenza Vaccine (LAIV) Sales Market Share, 2018-2029
Figure 37. China Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2029
Figure 41. India Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share, 2018-2029
Figure 43. By Country - South America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share, 2018-2029
Figure 44. Brazil Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Market Share, 2018-2029
Figure 48. Turkey Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$, Mn), 2018-2029
Figure 52. Global Live Attenuated Influenza Vaccine (LAIV) Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Live Attenuated Influenza Vaccine (LAIV) by Region, 2022 VS 2029
Figure 54. Live Attenuated Influenza Vaccine (LAIV) Industry Value Chain
Figure 55. Marketing Channels

※参考情報

弱毒生インフルエンザワクチン（LAIV）は、インフルエンザウイルスを弱毒化したものであり、免疫系を刺激して抗体を生成させることで、インフルエンザに対する防御を提供するワクチンです。このワクチンは、主に鼻腔に投与される点が特徴で、従来のインフルエンザワクチンとは異なる点があります。

まず、LAIVの定義について説明します。LAIVとは「Live Attenuated Influenza Vaccine」の略称で、これは生きたが弱毒化されたインフルエンザウイルスを含むワクチンのことを指します。従来のワクチンが不活化ウイルスを使うのに対し、LAIVは生きたウイルスの特性を利用して、より自然に近い免疫応答を引き起こすことができます。LAIVは特に小児のインフルエンザ予防に効果的とされ、多くの国で接種が推奨されています。

次に、LAIVの特徴について詳しく見ていきましょう。このワクチンは、従来の注射型（不活化ワクチン）とは異なり、鼻スプレー形態で投与されます。これは、ワクチン接種者の鼻粘膜で免疫応答を引き起こすため、潜在的な感染経路である上気道からの直接的な対応が可能になります。また、LAIVは、接種後の免疫形成が速く、おおよそ2週間以内に抗体が生成され、さらなる感染に対して即効性のある防御を提供します。

LAIVの種類としては、主にトリバレント（3成分）型と四 valent（4成分）型の2つがあります。トリバレントLAIVは、インフルエンザA型2種類（H1N1, H3N2）とインフルエンザB型1種類に対して免疫を誘導します。一方、四 valent LAIVでは、インフルエンザB型の異なる系統を含むことで、さらなる防御効果を期待することができます。これにより、流行するウイルスに対してより広範囲な免疫賦活が可能となっています。

適用については、LAIVは主に小児や若年層において使用されることが多いです。特に従来のインフルエンザワクチンを接種することが難しい乳幼児や、注射を恐れる子供たちにとって、鼻スプレー型は非常に扱いやすいワクチン形態です。さらに、LAIVは比較的副作用が少ないとされ、インフルエンザウイルスに自然に曝露されている子供たちにおいて、その受容性が高いという特長もあります。

LAIVに関連する技術として、ウイルスの弱毒化技術が挙げられます。これは、ウイルスの遺伝子を改変することによって、病原性を失わせつつも免疫系が認識できる形で残す技術です。この技術は、生産プロセスにおいて厳密な管理が求められ、特に、安全性の確保において重要な役割を担っています。加えて、ウイルスの適応変異を利用して、常に流行する株に即応したワクチン製造ができる点でも、これらの技術は重要です。

さらに、LAIVの効果を向上させるための研究も進められています。例えば、副効果を抑えるための新しい配合物や、投与方法を工夫することで、免疫応答を強化するための研究が行われています。また、特に高リスク群（妊婦、高齢者、基礎疾患を持つ人々など）に向けて、LAIVの適用可能性についても検討が進まれており、有効性や安全性のデータが蓄積されています。

最後に、LAIVの導入は公衆衛生政策においても重要な位置を占めています。インフルエンザウイルスは変異を繰り返すため、予防接種戦略もその変化を反映する必要があります。学校や地域社会での集団接種プログラムにおいて、LAIVを利用することで、特に子供たちの間でのウイルスの蔓延を抑制する効果が期待されます。このように、LAIVはインフルエンザに対する防御の一環として、ますます重要な役割を果たしていると言えるでしょう。

以上のように、弱毒生インフルエンザワクチン（LAIV）は、その特有の投与方法、迅速な免疫応答、さまざまな型といった特徴により、効果的なインフルエンザの予防手段として広く使用されていることがわかります。今後もさらなる研究が進み、安全かつ効果的なワクチンが開発されることが期待されます。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 弱毒生インフルエンザワクチン（LAIV）の世界市場見通し2023年-2029年(Live Attenuated Influenza Vaccine (LAIV) Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

弱毒生インフルエンザワクチン（LAIV）の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp